Comparative Pharmacology
Head-to-head clinical analysis: KANAMYCIN versus KANTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANAMYCIN versus KANTREX.
KANAMYCIN vs KANTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
15 mg/kg/day IM or IV in divided doses every 12 hours. Maximum daily dose: 1.5 g.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in patients with normal renal function (creatinine clearance >80 mL/min). In anuria, half-life may extend to 50-100 hours, necessitating dose adjustment based on renal function.
Clinical Note
moderateKanamycin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Kanamycin."
Clinical Note
moderateKanamycin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Kanamycin."
Clinical Note
moderateKanamycin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Kanamycin."
Clinical Note
moderateKanamycin + Acetyldigitoxin
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Primarily renal excretion via glomerular filtration; approximately 80-90% of administered dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Kanamycin."